GLTO Projected Dividend Yield
COM/GALECTO INC ( NASDAQ : GLTO )Galecto, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on developing novel treatments for cancer and liver diseases. Co.'s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). 21 YEAR PERFORMANCE RESULTS |
GLTO Dividend History Detail GLTO Dividend News GLTO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |